Efalizumab-induced isolated cerebral lupus-like syndrome

Neurology

Volumn 72, Issue 1, 2009, Pages 96-97

  Wendt, M ^a   Wohlrab, J ^a   Zierz, S ^a   Deschauer, M ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; EFALIZUMAB; FUMARIC ACID ETHYL ESTER; HEMOGLOBIN; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ANTIBODY TITER; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DISORIENTATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ERYTHROCYTE COUNT; HEMATOCRIT; HUMAN; LABORATORY TEST; LUPUS LIKE SYNDROME; MALE; MEMORY DISORDER; MOTOR DYSFUNCTION; ORGANIC PSYCHOSYNDROME; PRIORITY JOURNAL; PSORIASIS; TREATMENT OUTCOME; TREATMENT RESPONSE; BRAIN VASCULITIS; CHEMICALLY INDUCED DISORDER; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; HUMANS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; MALE; MIDDLE AGED; MOVEMENT DISORDERS;

EID: 63849205162     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000338627.07348.d8     Document Type: Article

References (6)

1. Vasoo S. Drug-induced lupus: an update. Lupus 2006;15: 757-761.
2. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 2007;26:6-14.
3. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-R551.
4. Kerns MJ, Graves JE, Smith DI, Heffernan MP. Off-label uses of biologic agents in dermatology: a 2006 update. Semin Cutan Med Surg 2006;25:226-240.
5. Clayton TH, Ogden S, Goodield M. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dematol 2006;54:892-895.
6. Bentley DD, Graves JE, Smith DI, Hefernan MP. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dematol 2006;54:S242-243.